MELBOURNE, Australia, May  20, 2026  (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (NASDAQ:PPCB) (&#34;Propanc&#34; or the &#34;Company&#34;), a biopharmaceutical company focused on developing novel treatments for chronic diseases,

PPCB

Propanc Biopharma's CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade

Propanc Biopharma Targets Pancreatic Cancer Breakthroughs with Upcoming Trials

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>MELBOURNE, Australia, May  20, 2026  (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (NASDAQ:PPCB) (&amp;#34;Propanc&amp;#34; or the &amp;#34;Company&amp;#34;), a biopharmaceutical company focused on developing novel treatments for chronic diseases,</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Propanc Biopharma anticipates substantial breakthroughs in pancreatic cancer treatments, driven by new clinical data on KRAS mutations and combination therapies. The company plans a pivotal Phase 1b clinical trial for its lead product, PRP, to improve patient outcomes, signaling potential long-term growth in a challenging market.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Propanc&#039;s CEO forecasts breakthroughs in pancreatic cancer treatments.</li><li>New KRAS-targeting trials show improved survival rates in pancreatic cancer.</li><li>Combination therapies indicate survival improvements from 22% to 42%.</li><li>Propanc plans Phase 1b trial with lead asset PRP this year.</li><li>PRP received Orphan Drug Designation for pancreatic cancer in 2017.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Revolution Medicines Inc. (RVMD)</strong>: Reported advancements in pancreatic cancer therapies could influence investor sentiment in the sector.</li><li><strong>Erasca Inc. (ERAS)</strong>: Progress in developing treatments may contribute to competitive dynamics affecting PPCB.</li></ul>
  </section>

  <section data-block="category">
    <h3>Industry News</h3>
    <p>This falls under &#039;Industry News,&#039; as it reflects significant developments in cancer treatments and Propanc&#039;s strategic response to market trends. Their innovative approach could position them favorably in a competitive landscape.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Positive trial results for PRP could significantly increase PPCB&#039;s market value.</li><li>Successful advancement in clinical trials might attract strategic partnerships or funding.</li><li>Growing interest in cancer treatment innovations can enhance investor sentiment towards PPCB.</li><li>Delays or failures in trial timelines may lead to a negative price reaction.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>PPCB&#039;s PRP achieved FDA Orphan Drug Designation in 2017.</li><li>New KRAS-targeted therapies show 13 months survival versus 7 months for standard treatments.</li><li>Combination therapies improved one-year survival rates from 22% to 42%.</li><li>Phase 1b trial expected to commence later this year with 30-40 patients.</li><li>PRP targets cancer stem cells to prevent recurrence and metastasis.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Buy PPCB as ongoing clinical advancements could enhance its valuation over the next year.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>MELBOURNE, Australia, May  20, 2026  (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/PPCB">PPCB</a>) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that the Company's CEO, Mr. James Nathanielsz, forecasts new medical breakthroughs in the fight against pancreatic cancer over the next decade. Recent developments in treatment reflect a level of progress that has been difficult to achieve in this field. Clinical stage companies like Revolution Medicines Inc. and Erasca Inc. have demonstrated significant advancements in this field.</p>  <p>New clinical data from a late-stage trial targeting KRAS mutations, which are present in many pancreatic cancer cases, showed a meaningful improvement in overall survival. Patients receiving the targeted therapy lived approximately 13 months compared to about 7 months with standard treatment. For a disease where outcomes have remained largely unchanged for decades, this represents an important step forward.</p>  <p>At the same time, additional data from combination therapy approaches are reinforcing a broader trend. In one study, a treatment designed to improve tumor penetration and support immune response increased one year survival rates to roughly 42%, compared to 22% with chemotherapy alone. These types of results are beginning to show that progress is more likely when multiple biological mechanisms are addressed together rather than in isolation. What stands out across these developments is not only the improvement in outcomes, but also what they reveal about the nature of pancreatic cancer. This is a disease driven by complex signaling pathways and supported by a highly resistant tumor environment. Targeting a single pathway, even one as important as KRAS, may not be sufficient on its own.</p>  <p>"From a broader perspective, these findings reinforce the importance of continuing to deepen our understanding of the underlying biology that drives both growth and resistance. While these advances are encouraging, survival outcomes remain limited, and there is still significant work to be done," said Mr. Nathanielsz. "At Propanc, we view this progress as part of a larger shift toward more biologically informed treatment strategies. Continued research into the mechanisms that support tumor persistence and recurrence will be critical in improving outcomes for patients facing this disease."</p>  <p>Propanc's lead asset, PRP, achieved Orphan Drug Designation status from the US Food and Drug Administration (USFDA) for the treatment of pancreatic cancer in 2017. Compassionate use data published in <em>Scientific Reports</em>, an online <em>Nature</em> journal, administering a once daily suppository of trypsinogen and chymotrypsinogen in a fixed combination of 8.92mg ea., resulted in 3 out of 4 patients significantly exceeding life expectancy from terminal pancreatic cancer with no severe or even serious side effects observed from treatment (2017).</p>  <p>The Company plans to file a Clinical Trial Application (CTA) in Australia for a Phase 1b, First-In-Human, Maximum Tolerated Dose study in 30 – 40 advanced cancer patients suffering from solid tumors using PRP in an I.V. formulation administered once weekly later this year. It will be at significantly higher doses than the compassionate use study based on non-clinical safety and tolerability data translating to a safe starting dose in humans. After Phase 1 completion, the Company plans to then undertake two, Phase 2, 60 patient studies in pancreatic and ovarian cancers to establish proof of concept for each therapeutic indication.</p>  <p><strong>About Propanc Biopharma, Inc.</strong></p>  <p>Propanc Biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/PPCB">PPCB</a>) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company's lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.</p>  <p><strong>More information:</strong> <a href="https://www.globenewswire.com/Tracker?data=vZ1Qr_MIbPHaf2c_mn8DSRhf7n7QJZ0uy3unEaA2BieDzVfWjw3eTcN1DbES7zQXiEYY27Ix7uVSxjlgBWCBmQ==" rel="nofollow" target="_blank">www.propanc.com</a></p>  <p><strong>Forward-Looking Statements</strong></p>  <p>All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company's expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as "may," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company's control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under "Risk Factors" in the prospectus related to the proposed offering and those described in the Company's filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.</p>  <p><strong>Company:</strong><br></br>Propanc Biopharma, Inc.<br></br>James Nathanielsz</p>  <p>+61-3-9882-0780</p>  <p><a href="https://www.globenewswire.com/Tracker?data=0rnFL3Jbv2unOtewv9MYNOhOOBt9pKMkD4XPbuFBydlClVm92lJONSNqG0IJuuSISm_kyxpnqwiq4xp7x9VTuhTNqTptA11o8GNdXzVaiVw=" rel="nofollow" target="_blank"><u>info@propanc.com</u></a></p>  <p><strong>Investor Contact:</strong></p>  <p><a href="https://www.globenewswire.com/Tracker?data=pENweFro9cTbvZ2pbOhdj5e8o8zOde4mbvOIzqdQ-ZRSZ_ekYHsUobS74d9WcG_mLFlGJQMJ9Gm3RW_lr77bhZA97xxFp5PqMmX6W_eO96g=" rel="nofollow" target="_blank"><u>irteam@propanc.com</u></a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTcyMTIwOSM3NjA1ODYyIzIyOTExMTI="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/Y2Y2ZGFhZmQtNDFlNS00N2MzLTg3NDctNmY1NDQ5NDU0ZWUzLTEzMDI2NjItMjAyNi0wNS0yMC1lbg==/tiny/Propanc-Biopharma-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/0de2a486-4708-45bf-a406-f462ad395dec"><img src="https://ml.globenewswire.com/media/0de2a486-4708-45bf-a406-f462ad395dec/small/propanc-logo-png.png" border="0" width="150" height="34" alt="Primary Logo"></img></a></p>

Propanc Biopharma anticipates substantial breakthroughs in pancreatic cancer treatments, driven by new clinical data on KRAS mutations and combination therapies. The company plans a pivotal Phase 1b clinical trial for its lead product, PRP, to improve patient outcomes, signaling potential long-term growth in a challenging market.

Propanc Biopharma's CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Industry News

Related News